<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-1624</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИКА И ФАРМАКОТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR THE PRACTITIONER</subject></subj-group></article-categories><title-group><article-title>ВОЗМОЖНОСТИ КОРРЕКЦИИ ОКСИДАТИВНОГО СТРЕССА И ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА ИНГИБИТОРОМ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА</article-title><trans-title-group xml:lang="en"><trans-title>Oxidative stress and endothelial dysfunction correction with ACE inhibitor therapy in patients with myocardial infarction and Type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Задионченко</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zadionchenko</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лексина</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Leksina</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тимофеева</surname><given-names>Н. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Timofeeva</surname><given-names>N. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шехян</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shekhyan</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миронова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mironova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терехова</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Terekhova</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра терапии и семейной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Московский государственный медико-стоматологический университет</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2008</year></pub-date><volume>0</volume><issue>5</issue><fpage>40</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Задионченко В.С., Лексина К.С., Тимофеева Н.Ю., Шехян Г.Г., Миронова М.А., Терехова Т.М., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Задионченко В.С., Лексина К.С., Тимофеева Н.Ю., Шехян Г.Г., Миронова М.А., Терехова Т.М.</copyright-holder><copyright-holder xml:lang="en">Zadionchenko V.S., Leksina K.S., Timofeeva N.Y., Shekhyan G.G., Mironova M.A., Terekhova T.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/1624">https://russjcardiol.elpub.ru/jour/article/view/1624</self-uri><abstract/><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>инфаркт миокарда</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>оксидативный стресс</kwd><kwd>дисфункция эндотелия</kwd><kwd>возможности коррекции</kwd><kwd>зофеноприл</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Myocardial infarction</kwd><kwd>Type 2 diabetes mellitus</kwd><kwd>oxidative stress</kwd><kwd>endothelial dysfunction</kwd><kwd>corrective potential</kwd><kwd>zofenopril</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Зенков Н.К., Ланкин В.З., Меньщикова Е.Б. Окислительный стресс. Биохимический и патофизиологические аспекты. Москва: МАИК «Наука/Интерпериодика», 2001; 343 с.</mixed-citation><mixed-citation xml:lang="en">Зенков Н.К., Ланкин В.З., Меньщикова Е.Б. Окислительный стресс. Биохимический и патофизиологические аспекты. Москва: МАИК «Наука/Интерпериодика», 2001; 343 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: PRO ET CONTRA (Пособие для врачей). Москва: РКНПК МЗ РФ, 2006; 78-1.</mixed-citation><mixed-citation xml:lang="en">Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: PRO ET CONTRA (Пособие для врачей). Москва: РКНПК МЗ РФ, 2006; 78-1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы//Кардиология. 2000; 40(7): 486-1.</mixed-citation><mixed-citation xml:lang="en">Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы//Кардиология. 2000; 40(7): 486-1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Величковский Б.Т. Свободнорадикальное окисление как звено срочной и долговременной адаптации организма к факторам окружающей среды//Вестник РАМН. 2001, №5, С. 455-1.</mixed-citation><mixed-citation xml:lang="en">Величковский Б.Т. Свободнорадикальное окисление как звено срочной и долговременной адаптации организма к факторам окружающей среды//Вестник РАМН. 2001, №5, С. 455-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna//Сердце. 2004; 1(3): 58.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Александров А.А. Диабетическое сердце: Causa Magna//Сердце. 2004; 1(3): 58.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Панченко Е.П. Ишемическая болезнь сердца и сахарный диабет -коварный тандем//Сердце. 2004; 1(3): 91-2.</mixed-citation><mixed-citation xml:lang="en">Панченко Е.П. Ишемическая болезнь сердца и сахарный диабет -коварный тандем//Сердце. 2004; 1(3): 91-2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Borghi C. et al. Double-blind comparison between Zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study//Am Heart J 2003; 145: 808-7.</mixed-citation><mixed-citation xml:lang="en">Borghi C. et al. Double-blind comparison between Zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study//Am Heart J 2003; 145: 808-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Nigris Fet al. Chronic treatment with sulfhydryl angiotensinconverting enzyme inhibitors reduces susceptibility of plasma LDL to «in vitro» oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice//Int J Cardiol. 2001; 81(23-): 1071-5;</mixed-citation><mixed-citation xml:lang="en">De Nigris Fet al. Chronic treatment with sulfhydryl angiotensinconverting enzyme inhibitors reduces susceptibility of plasma LDL to «in vitro» oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice//Int J Cardiol. 2001; 81(23-): 1071-5;</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Flak T.A., Goldman W.E. Autotoxicity of nitric oxide in airway disease//Am. J. Respir Crit. care Med. 1996. Vol. 154. P 2022-06.</mixed-citation><mixed-citation xml:lang="en">Flak T.A., Goldman W.E. Autotoxicity of nitric oxide in airway disease//Am. J. Respir Crit. care Med. 1996. Vol. 154. P 2022-06.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Flather M.D., Yisuf S., Kober L. et al. Long-term ACE-inhibitor therapy in heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients//Lancet 2000; 355: 15751 -581.</mixed-citation><mixed-citation xml:lang="en">Flather M.D., Yisuf S., Kober L. et al. Long-term ACE-inhibitor therapy in heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients//Lancet 2000; 355: 15751 -581.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Haffner S.M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction//N. Engl. J. Med.1998; 339: 2292-34.</mixed-citation><mixed-citation xml:lang="en">Haffner S.M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction//N. Engl. J. Med.1998; 339: 2292-34.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Melchior T. Kober L., Madsen C.R. et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation//Eur Heart J. 2000; 21: 19371-943.</mixed-citation><mixed-citation xml:lang="en">Melchior T. Kober L., Madsen C.R. et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation//Eur Heart J. 2000; 21: 19371-943.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Scribner A.W. et al.: The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress//Eur J. Pharmacol 2003; 482: 959-9.</mixed-citation><mixed-citation xml:lang="en">Scribner A.W. et al.: The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress//Eur J. Pharmacol 2003; 482: 959-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Timmis A.D. Diabetic Heart disease: clinical considerations//Heart 2001; 85: 4634-69.</mixed-citation><mixed-citation xml:lang="en">Timmis A.D. Diabetic Heart disease: clinical considerations//Heart 2001; 85: 4634-69.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Torp-Pedersen C., Rask-Madsen C., Gustafsson I. et al. Diabetes mellitus and cardiovascular risk: just another risk factor?//Eur</mixed-citation><mixed-citation xml:lang="en">Torp-Pedersen C., Rask-Madsen C., Gustafsson I. et al. Diabetes mellitus and cardiovascular risk: just another risk factor?//Eur</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Heart J. 2003; 5(suppl. F.): F23-F32.</mixed-citation><mixed-citation xml:lang="en">Heart J. 2003; 5(suppl. F.): F23-F32.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Timmis A.D. Diabetic heart disease: clinical considerations//Heart. 2001; 85: 4634-69.</mixed-citation><mixed-citation xml:lang="en">Timmis A.D. Diabetic heart disease: clinical considerations//Heart. 2001; 85: 4634-69.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
